Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 103,491

Document Document Title
WO/2014/142255A1
Provided is a heterocyclic compound exhibiting an RORγt-inhibiting action. Specifically provided is a compound represented by formula (I) or a salt thereof. [In the formula, Ar indicates partial formulas (1) through (5), Q indicates a b...  
WO/2014/140310A1
The present invention relates to pyrrolidine derivatives of formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrro...  
WO/2014/144342A1
Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB recept...  
WO/2014/141280A1
Compositions, methods and devices for intranasal administration of Rasagiline or a pharmaceutically acceptable salt thereof are disclosed. The compositions, devices and methods are for treating depression, Parkinson's disease and/or moto...  
WO/2014/144654A1
Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including A...  
WO/2014/143990A1
Preparations derived from placental materials and methods of making and using same, the preparations including a first preparation composed of placental membranes digested in collagenase, a second preparation composed of multipotent cell...  
WO/2014/139161A1
One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs...  
WO/2014/142547A1
The present invention relates to a composition for neuroprotection comprising a phenyl carbamate compound and a method for providing neuroprotection therewith. The present invention ensures the enhancement of neuroprotection, such that i...  
WO/2014/139458A1
Disclosed in the invention are a fused ring compound containing pyrimidine or pyridine and the use thereof as an anti-tumour drug. teT fused ring compound is a compound as shown by formula (I) or a pharmaceutical acceptable salt thereof;...  
WO/2014/140279A1
The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein R1, R2, R3, R4 and R5 are as defined herein, as inhibitors...  
WO/2014/142549A1
The present invention relates to a composition for preventing or treating a memory loss related disease comprising a phenyl carbamate compound and a method for preventing or treating various diseases related to loss of memory therewith. ...  
WO/2014/146069A1
Pharmaceutical compositions and methods of use therefor for reducing the desire to engage in smoking are disclosed. More specifically, the pharmaceutical composition utilizes an active ingredient to reduce the side effects of smoking ces...  
WO/2014/140510A1
A compound according to formula (I) or a hydrate, solvate, or pharmaceutically acceptable salt thereof: wherein where the integers Q, R2, A, R1, Z1, Z2, and Z3 are as defined in claim 1.  
WO/2014/146111A3
Provided herein, inter alia, are methods and compositions for achieving an analgesic effect in subjects in need thereof.  
WO/2014/140246A1
The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suit...  
WO/2014/143201A1
A short treatment with noribogaine shows promise for treating drug dependency. Many opioid addicts are treated with methadone. We have found that giving noribogaine to mammal concurrently being administered methadone surprisingly exacerb...  
WO/2014/143646A1
The present invention is directed to an aqueous formulation of S-ketamine hydrochloride, preferably for nasal administration, wherein the formulation does not contain an antimicrobial preservative.  
WO/2014/145316A1
The present disclosure is directed to methods of identifying neuroprotective PKC activators comprising analyzing candidate PKC activators to determine if they are non-tumorigenic, non-toxic, accessible to the brain, have α and ε specif...  
WO/2014/143146A1
Methods of therapeutic treatment using monomethyl fumarate are disclosed.  
WO/2014/138812A1
The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2- ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co- crystals, and pharmaceutical compositions thereof. The inventio...  
WO/2014/139318A1
An application of a phthalide compound in preparing a medicament. The medicament is specially used for promoting a stem cell to secrete one of the following items: telomerase, a neurotrophic factor (brain-derived neurotrophic factor, BDN...  
WO/2014/143579A1
The present invention provides a compound of Formula (I): wherein R is H or F; and A is:(A), (B), (C) or (D); or a pharmaceutically acceptable salt thereof.  
WO/2014/146059A1
There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl. There are additionally provided pharmaceutical compositions. There are additionally p...  
WO/2014/144115A1
The present invention relates to a fixed dosage unit, and methods for treating schizophrenia comprising administering the fixed dosage unit. More specifically, the present invention relates to a fixed dosage unit that reduces the inciden...  
WO/2014/143992A1
Provided herein are compositions, kits and methods related to the treatment of one or more lysosomal storage diseases (LSDs) in a subject and methods of identifying agents that are useful for the treatment of one or more LSDs. The compos...  
WO/2014/144508A2  
WO/2014/141091A1
Disclosed are compounds of the Formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and m are as described herein, as modulators of the nicotinic acetylcholine receptors, particularly the α7 subtype, their tautomeric forms, stereoisomers, an...  
WO/2014/140184A1
The present invention relates to compounds of the formula (I), the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined i...  
WO/2014/144512A4
A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are meth...  
WO/2014/142550A1
The present invention relates to a composition for preventing or treating a psychiatric disorder comprising a phenyl carbamate compound and a method for preventing or treating a psychiatric disorder therewith. The present invention provi...  
WO/2014/143799A4
Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.  
WO/2014/139681A1
The present invention relates to crystalline forms of cis-(E)-4-(3-Fluorophenyl)-2',3',4',9'- tetrahydro-N,N-dimethyl-2'-(1-oxo-3-phenyl-2-propenyl)-spiro [cyclohexane-1, 1 '[1 H]- pyrido[3,4-b]indol]-4-amine, pharmaceutical compositions...  
WO/2014/138518A3
Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (DA), serotonin (5-HT), and/or norepinephr...  
WO/2014/138003A1
The present disclosure relates generally to compositions and methods for treating a subject with a neurodegenerative disease and/or disorder) such as an injured spinal cord, stroke, or ALS. Such methods include administering to a subject...  
WO/2014/134772A1
Provided are indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which LRRK2 kinase is involved. Also provided are pharmaceutical compositions comprising these compounds...  
WO/2014/136305A1
The present invention relates to a morphinan derivative as represented by general formula (I); a tautomer or stereoisomer of said compound; a pharmaceutically acceptable salt thereof; a solvate of the morphinan derivative or of a tautome...  
WO/2014/138484A1
PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase ...  
WO/2014/134774A1
Disclosed are indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which LRRK2 kinase is involved. Also disclosed are pharmaceutical compositions in the prevention or tre...  
WO/2014/135529A1
This invention relates to a mixture of at !east three fatty acids selected from palmitic acid, oleic acid, stearic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), ...  
WO/2014/134776A1
The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention i...  
WO/2014/134692A1
The composition of extracts from the genus Hippeastrum and their components is intended for the production of pharmaceuticals and dietary supplements. The composition consists of galanthamine from 40% to 98%, haemanthamine from 0.01 % to...  
WO/2014/136717A1
Provided are: a novel transdermally absorbable pharmaceutical composition which has such characteristic properties that the skin permeability of duloxetine or a pharmaceutically acceptable salt thereof contained in the pharmaceutical com...  
WO/2014/137849A1
The present invention discloses pyridoinolobenz[b,e]azepine derivatives of Formula 1,wherein X is -O-, -S-, -SO-, or -SO2-. Y is a single bond or a double bond. A and B are independently -(CH2)n-; and 'n' varies from 0 to 3. R1 to R9 are...  
WO/2014/136730A1
A method of producing, at a high conversion rate and with good reproducibility, a 3‒[(S)‒7‒bromo‒2‒(2‒oxo‒propylamino)‒5‒pyr idine‒2‒yl‒3H‒1,4‒benzodiazepine‒3‒yl]methyl propionate through the oxidization ...  
WO/2014/136075A1
The present invention relates to new histamine H 3(H 3) receptor subtype selective ligands of the general formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/ or hydrates and/or solvates thereo...  
WO/2014/136118A1
An aspect of embodiments of the invention relates to a method for preventing and/or treating post-traumatic stress disorder (PTSD) by administration to a subject an effective amount of melanocortin receptor antagonist. Additional embodim...  
WO/2014/134380A1
One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac...  
WO/2014/133022A1
A compound represented by general formula (I) [wherein R represents a hydrogen atom, a C1-6 alkyl group or the like; R1 represents a C1-6 alkyl group, a C1-6 alkoxy group or the like; R2 represents a halogen atom, a C1-6 alkyl group, a C...  
WO/2014/132430A1
The purpose of the present invention is to provide a ginsenoside composition which is capable of exerting a specifically high efficacy against various symptoms and diseases including unidentified clinical syndrome. The ginsenoside compos...  
WO/2014/132982A1
Ingestion of a composition which contains either Lactobacillus gasseri or both Lactobacillus gasseri and αLA as an active ingredient brings about enhancement of immune responses and a reduction of physical fatigue.  

Matches 501 - 550 out of 103,491